Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia

Date: September 23, 2019 Issue #:  1581Summary:  Lefamulin (Xenleta– Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin(Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Amoxicillin Ampicillin/sulbactam Avelox Azithromycin Cefotaxime Cefpodoxime ceftaroline Ceftriaxone Chlamydophila pneumoniae Doxycycline Fluoroquinolones Haemophilus influenzae lefamulin Levaquin Levofloxacin Linezolid meth Source Type: research